SFA is a clinical-stage biotech with a novel platform for chronic inflammatory diseases. Over 125M people suffer from autoimmune diseases. We have 6 oral drugs targeting autoimmune diseases and cancer. We have an IND, Orphan Drug Designation (liver cancer), are in Phase 1b (psoriasis), and are raising funds for Phase 2. We will license these drugs for >$500M. We have >200 yrs of experience, 40 drugs and 8 exits. Our vision is to change Medicine.